United Therapeutics Corp. Rating Increased to Outperform at Zacks (UTHR)
United Therapeutics Corp. (NASDAQ:UTHR) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research report issued to clients and investors on Monday, American Banking News.com reports. The firm currently has a $103.00 target price on the stock. Zacks‘ price objective indicates a potential upside of 20.50% from the company’s current price.
Zacks‘ analyst wrote, “United Therapeutics reported second-quarter 2013 earnings of $1.52 per share, well above the year-ago earnings of $1.34 and the Zacks Consensus Estimate of $1.47. Second quarter revenues increased 24.4% to $280.6 million, beating the Zacks Consensus Estimate of $249 million. The company maintained its 2013 guidance. We believe the company is well-positioned to gain share in the pulmonary arterial hypertension (PAH) market. Lead product, Remodulin, continues to look very strong in both the intravenous (IV) and subcutaneous (SC) forms. Tyvaso and Adcirca should also contribute significantly to revenues as patient acceptance increases. Tyvaso’s performance has been improving and the product is on track to overtake Remodulin revenues in the next couple of years. Based on these factors, we are upgrading United Therapeutics to Outperform.”
Shares of United Therapeutics Corp. (NASDAQ:UTHR) traded down 0.82% during mid-day trading on Monday, hitting $84.78. The stock had a trading volume of 263,241 shares. United Therapeutics Corp. has a 52-week low of $44.51 and a 52-week high of $85.92. The stock has a 50-day moving average of $76.23 and a 200-day moving average of $68.75. The company has a market cap of $4.232 billion and a price-to-earnings ratio of 14.74.
United Therapeutics Corp. (NASDAQ:UTHR) last announced its earnings results on Thursday, July 25th. The company reported $1.52 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.47 by $0.05. The company had revenue of $280.60 million for the quarter, compared to the consensus estimate of $250.17 million. During the same quarter in the prior year, the company posted $1.34 earnings per share. The company’s quarterly revenue was up 24.4% on a year-over-year basis.
A number of other firms have also recently commented on UTHR. Analysts at Goldman Sachs Group Inc. raised their price target on shares of United Therapeutics Corp. from $55.00 to $56.00 in a research note to investors on Wednesday, September 18th. Separately, analysts at Argus raised their price target on shares of United Therapeutics Corp. from $75.00 to $85.00 in a research note to investors on Monday, August 5th. They now have a “buy” rating on the stock. Finally, analysts at Guggenheim raised their price target on shares of United Therapeutics Corp. from $61.00 to $69.00 in a research note to investors on Tuesday, July 30th. They now have a “neutral” rating on the stock. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $66.40.
In other United Therapeutics Corp. news, COO Roger Jeffs unloaded 10,000 shares of the company’s stock in a transaction that occurred on Friday, October 4th. The stock was sold at an average price of $85.48, for a total transaction of $854,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.